Home Compare BMY vs MRK
Stock Comparison · Industry comparison · Drug Manufacturers - General

Bristol-Myers Squibb Company vs Merck & Co.: Which Stock Looks Stronger in 2026?

The structural profiles are close, with Merck carrying a narrow edge on growth. Bristol-Myers Squibb Company still has the edge on growth, which keeps the comparison from looking entirely one-sided. The market setup is mixed, without a decisive signal in either direction. The market is not adding a decisive signal either way — the structural read carries the weight.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

Growth points more clearly toward Bristol-Myers Squibb Company, even if the broader score still leans toward Merck & Co., Inc..

INDUSTRY COMPARISON

Both operate in: Drug Manufacturers - General

This comparison is based on industry proximity, not on functional trajectory similarity. BMY and MRK share the same industry classification.

For a similarity-based comparison, see how BMY and Merck each position within their functional peer groups in AssetNext.

Peer-Relative Score
BMY
Bristol-Myers Squibb Company
61
Peer-Score
Signal qualityHigh
vs
MRK
Merck & Co., Inc.
63
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The clearest separation appears in growth.

Dimension spread: BMY vs MRK Profitability 38 62 Stability 56 57 Valuation 86 88 Growth 62 31 BMY MRK
Gap Ranking
#1 Growth +31
#2 Profitability +24
#3 Valuation +2
#4 Stability +1
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for BMY and MRK Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer BMYMRK Relative valuation Structural strength

The setup is mixed: neither company clearly combines the stronger profile with the more supportive price setup.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Growth
On growth, Bristol-Myers Squibb Company is positioned higher in the group, while Merck & Co., Inc. is closer to the middle.
Profitability
On profitability, Merck & Co., Inc. is positioned higher in the group, while Bristol-Myers Squibb Company is closer to the middle.
Growth — Dominant Gap
BMY
62
MRK
31
Gap+31in favour of BMY

The current lead is backed by a stronger multi-year growth trajectory.

What keeps the gap from being one-sided

Bristol-Myers Squibb Company still carries lower volatility exposure — that difference is real enough to prevent the comparison from becoming one-sided.

What this means for the comparison

Growth is the clearest driver of the lead, with profitability adding further support — though growth still provides a real counterweight.

Explore full peer positioning in AssetNext

Break down the BMY vs MRK comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Other comparisons with conflicting dimension signals

Explore how BMY and MRK each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.